Janssen Pharmaceuticals, Inc. entered into an asset purchase agreement to acquire Assets of MeiraGTx Holdings plc from MeiraGTx Holdings plc for approximately $420 million.

Janssen Pharmaceuticals, Inc. entered into an asset purchase agreement to acquire Assets of MeiraGTx Holdings plc from MeiraGTx Holdings plc (NasdaqGS:MGTX) for approximately $420 million on December 20, 2023. As part of consideration $65 million will pay at signing, an additional $50 million anticipated in the first quarter of 2024, with the remaining $15 million in milestone payments expected later in 2024. MeiraGTx will receive up to a further $285 million upon first commercial sales of bota-vec in the U.S. and EU and for manufacturing technology transfer.

Evercore Group L.L.C. acted as financial advisor to MeiraGTx Holdings plc (NasdaqGS:MGTX) and Morgan, Lewis & Bockius LLP acted as legal advisor to MeiraGTx Holdings plc (NasdaqGS:MGTX).